A systematic review and meta-analysis on the levels of brain-derived neurotrophic factor in insomnia patients with and without comorbid depression

Norouzi‬, Ebrahim; Mohammadi, Reza; Fadaei, Reza; Moradi, Mohammad‐Taher; Hosseini, Hossein; Rezaie, Leeba; Khazaie, Habibolah

doi:10.1080/09291016.2023.2222239

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies showed that neurotropic agents play an important role in the pathogenesis of depression as well as depression treatments [ 83 ]. Among the most widespread neurotrophic factors is brain-derived neurotrophic factor (BDNF), which is expressed in the hippocampus as well as the cerebral cortex [ 84 , 85 ]. Clinical and pharmacological studies showed that BDNF concentration decreases in the serum of patients with MDD.…”

Section: Discussionmentioning

confidence: 99%

Effects of Aphrodite (an Herbal Compound) on SSRI-Induced Sexual Dysfunctions and Depression in Females with Major Depressive Disorder: Findings from a Randomized Clinical Trial

Shahmoradi,

Davarinejad,

Brühl

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: Almost by default, people with major depression disorder (MDD) also report sexual health issues. This holds even more true when sexual dysfunctions are SSRI-induced. Herbal compounds may have the power to counterbalance such sexual dysfunctions, though research is still scarce. Therefore, we assessed females with diagnosed MDD treated with a standard SSRI (sertraline) and reporting SSRI-induced sexual dysfunctions, and we asked whether compared to placebo, Aphrodite® (a blend of ginger, saffron, cinnamon, thistle, and Tribulus terrestris) may favorably impact on sexual dysfunctions, and on symptoms of depression, anxiety, and sleep disturbances. Materials and Methods: A total of 41 females (mean age: 35.05 years) with diagnosed MDD, treated with sertraline (a standard SSRI) at therapeutic dosages, and reporting SSRI-induced sexual dysfunction, were randomly assigned either to Aphrodite or to the placebo condition. At baseline and four and eight weeks later (study end), participants completed a series of self-rating questionnaires covering symptoms of sexual dysfunction, depression, anxiety, and sleep complaints. Results: Symptoms of sexual dysfunction, depression, and anxiety decreased over time, but more so in the Aphrodite condition, compared to the placebo condition (significant p-values and large effect sizes). Over time, sleep disturbances decreased irrespective of the study condition. Conclusions: The pattern of results suggests that compared to placebo, Aphrodite appeared to improve symptoms of sexual dysfunction, depression, and anxiety among females with diagnosed MDD and SSRI-induced sexual dysfunction. Further and similar studies should investigate the underlying psychophysiological mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%